Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesNabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09
Nabi Biopharmaceuticals announced that it has completed the sale of PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline PLC (GSK). The sale was announced in August of this year. Under the terms of the agreement, Nabi will receive cash payments of $21.5 million of which $20 million is associated with the PentaStaph transaction close, $1 million associated with the sale of a separate pre–clinical program for a vaccine against S.epidermedis, as well as $0.5 million as reimbursement for license fees and clinical materials previously manufactured for use in the Phase I trial.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09
Sponsor
Article Search
Sponsor